Actual Fiebig Stage of Participants by Inclusion Criterion for Acute and Early Human Immunodeficiency Virus Infection
| . | . | Actual Fiebig Stage . | . | |||||
|---|---|---|---|---|---|---|---|---|
| Inclusion AEHI Criterion . | Uninfected (n = 3) . | I (n = 6) . | II (n = 43) . | III (n = 56) . | IV (n = 23) . | V (n = 60) . | VI (n = 4) . | Total (N = 195) . |
| A (I/II) | 2 | 5 | 27 | 47 | 13 | 18 | 1 | 113 (57.9%) |
| B (III/IV) | 1 | 1 | 4 | 3 | 4 | 6 | 0 | 19 (9.7%) |
| C (V) | 0 | 0 | 0 | 0 | 2 | 32 | 3 | 37 (19.0%) |
| D (I/II) | 0 | 0 | 12 | 4 | 4 | 4 | 0 | 24 (12.3%) |
| E (I/II) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0%) |
| F (I/II) | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 (1.0%) |
| . | . | Actual Fiebig Stage . | . | |||||
|---|---|---|---|---|---|---|---|---|
| Inclusion AEHI Criterion . | Uninfected (n = 3) . | I (n = 6) . | II (n = 43) . | III (n = 56) . | IV (n = 23) . | V (n = 60) . | VI (n = 4) . | Total (N = 195) . |
| A (I/II) | 2 | 5 | 27 | 47 | 13 | 18 | 1 | 113 (57.9%) |
| B (III/IV) | 1 | 1 | 4 | 3 | 4 | 6 | 0 | 19 (9.7%) |
| C (V) | 0 | 0 | 0 | 0 | 2 | 32 | 3 | 37 (19.0%) |
| D (I/II) | 0 | 0 | 12 | 4 | 4 | 4 | 0 | 24 (12.3%) |
| E (I/II) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0%) |
| F (I/II) | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 (1.0%) |
Eligibility for enrollment was assessed using available test results to satisfy 1 of 6 study-specific criteria for acute and early human immunodeficiency virus (HIV) infection, each of which was mapped to an estimated protocol-defined Fiebig stage group (I/II, III/IV, or V). Actual Fiebig stage was determined using centralized testing of samples collected on the day of enrollment. See Table 1 for definitions of inclusion criteria for acute and early HIV infection. Abbreviation: AEHI, acute and early HIV infection.
Actual Fiebig Stage of Participants by Inclusion Criterion for Acute and Early Human Immunodeficiency Virus Infection
| . | . | Actual Fiebig Stage . | . | |||||
|---|---|---|---|---|---|---|---|---|
| Inclusion AEHI Criterion . | Uninfected (n = 3) . | I (n = 6) . | II (n = 43) . | III (n = 56) . | IV (n = 23) . | V (n = 60) . | VI (n = 4) . | Total (N = 195) . |
| A (I/II) | 2 | 5 | 27 | 47 | 13 | 18 | 1 | 113 (57.9%) |
| B (III/IV) | 1 | 1 | 4 | 3 | 4 | 6 | 0 | 19 (9.7%) |
| C (V) | 0 | 0 | 0 | 0 | 2 | 32 | 3 | 37 (19.0%) |
| D (I/II) | 0 | 0 | 12 | 4 | 4 | 4 | 0 | 24 (12.3%) |
| E (I/II) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0%) |
| F (I/II) | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 (1.0%) |
| . | . | Actual Fiebig Stage . | . | |||||
|---|---|---|---|---|---|---|---|---|
| Inclusion AEHI Criterion . | Uninfected (n = 3) . | I (n = 6) . | II (n = 43) . | III (n = 56) . | IV (n = 23) . | V (n = 60) . | VI (n = 4) . | Total (N = 195) . |
| A (I/II) | 2 | 5 | 27 | 47 | 13 | 18 | 1 | 113 (57.9%) |
| B (III/IV) | 1 | 1 | 4 | 3 | 4 | 6 | 0 | 19 (9.7%) |
| C (V) | 0 | 0 | 0 | 0 | 2 | 32 | 3 | 37 (19.0%) |
| D (I/II) | 0 | 0 | 12 | 4 | 4 | 4 | 0 | 24 (12.3%) |
| E (I/II) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0%) |
| F (I/II) | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 (1.0%) |
Eligibility for enrollment was assessed using available test results to satisfy 1 of 6 study-specific criteria for acute and early human immunodeficiency virus (HIV) infection, each of which was mapped to an estimated protocol-defined Fiebig stage group (I/II, III/IV, or V). Actual Fiebig stage was determined using centralized testing of samples collected on the day of enrollment. See Table 1 for definitions of inclusion criteria for acute and early HIV infection. Abbreviation: AEHI, acute and early HIV infection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
